## Contents of volume 99

No. 1 (pp 1-146) published August 10, 1989 No. 2 (pp 147-288) published August 31, 1989 No. 3 (pp 289-430) published September 29, 1989 No. 4 (pp 431-570) published November 2, 1989

This volume contains the following supplement: Clozapine (Leponex®/Clozaril®), Scientific update meeting. Montreux, Switzerland, October 31–November 1, 1988 S1–S128

Ackenheil M: Clozapine-pharmacokinetic investigations and biochemical effects in man S 32

Acquas E, Carboni E, Leone P, Di Chiara G: SCH 23390 blocks drug-conditioned place-preference and place-aversion: anhedonia (lack of reward) or apathy (lack of motivation) after dopamine-receptor blockade? 151

Adam K, Oswald I: Effects of repeated ritanserin on middle-aged poor sleepers

219

Adell A, García-Marquez C, Armario A, Gelpí E: Chronic administration of clomipramine prevents the increase in serotonin and noradrenaline induced by chronic stress 22

Alfredsson G, Wiesel F-A: Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment 322

Alphs LD → Bastani B Alvarez E → Artigas F Amori G → Hughes JR

Andersson A → Marcusson JO

Andorn AC, Vittorio JA, Bellflower J: <sup>3</sup>H-Spiroperidol binding in human temporal cortex (Brodmann areas 41–42) occurs at multiple high affinity states with serotonergic selectivity 520

Angst J, Stassen HH, Woggon B: Effect of neuroleptics on positive and negative symptoms and the deficit state S 41

Anisman H → Shanks N

Annett LE, Ridley RM, Gamble SJ, Baker HF: Social withdrawal following amphetamine administration to marmosets 222

Antelman SM → Caggiula AR Appel JB → Barrett RL

Archer T → Luthman J

Armario A → Adell A

Artigas F, Sarrias MJ, Martínez E, Gelpí E, Alvarez E, Udina C: Increased plasma free serotonin but unchanged platelet serotonin in bipolar patients treated chronically with lithium 328

Aul E → Caggiula AR

Back M → Mondadori C Bäckström I → Marcusson JO Baker HF → Annett LE

Bakshi VP → Kelley AE Baldry AG → Guyatt AR

Balkin TJ, O'Donnell VM, Kamimori GH, Redmond DP, Belenky G: Administration of triazolam prior to recovery sleep:

effects on sleep architecture, subsequent alertness and performance 526

Balster RL → Willetts J Barnes P → Krupp P

Baron JC, Martinot JL, Cambon H, Boulenger JP, Poirier MF, Caillard V, Blin J, Huret JD, Loc'h C, Maziere B: Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels 463

Barrett RL, Appel JB: Effects of stimulation and blockade of dopamine receptor subtypes on the discriminative stimulus properties of cocaine 13

Bastani B, Alphs LD, Meltzer HY: Development of the Clozaril Patient Management System S 122

Bastani B → Meltzer HY

Bättig K → Nil R Bech P → Loldrup D

Becker HC, Hale RL: Ethanol-induced locomotor stimulation in C57BL/6 mice following RO15-4513 administration 333

Beckmann H → Fritze J Belcher M → West R Belenky G → Balkin TJ

Beliflower J → Andorn AC

Berry SA → Gudelsky GA

Bird DC → Holloway FA
Blanchard J-C → Stutzmann J-M

Blin J → Baron JC

Bobelis DJ → Willetts J

Bone GHA, Majchrowicz E, Martin PR, Linnoila M, Nutt DJ: A comparison of calcium antagonists and diazepam in reducing ethanol withdrawal tremors 386

Born J, Kern W, Pietrowsky R, Sittig W, Fehm HL: Fragments of ACTH affect electrophysiological signs of controlled stimulus processing in humans 439

Bosch B → Leppig M
Boulenger JP → Baron JC
Brady JV → Hienz RD
Breeding M → Sanders-Bush E
Bryda M → Costello NL
Burnett S → Meltzer HY
Burton P → Mesotten F
Butcher LL → McGurk SR

Caggiula AR, Antelman SM, Aul E, Knopf S, Edwards DJ: Prior stress attenuates the analgesic response but sensitizes the corticosterone and cortical dopamine responses to stress 10 days later 233

Caggiula AR, Epstein LH, Stiller R: Changing environmental cues reduces tolerance to nicotine-induced anorexia

Caillard V → Baron JC Callaway E → Halliday R

Cambon H → Baron JC Carboni E → Acquas E

Carlson JN → Costello NL Cascella NG → Muntaner C

Casey DE: Clozapine: neuroleptic-induced EPS and tardive dyskinesia S 47 Cintrat P → Stutzmann J-M

Claas FHJ: Drug-induced agranulocytosis: review of possible mechanisms, and prospects for clozapine studies S 113

prospects for clozapine studies S 113
Clozaril Collaborative Study Group →
Kane JM

Coen KM → Corrigall WA Cohen PR → Cowen PJ

Cohen PR → Cowen PJ
Cohen PR → McCance SL

Cohen RM → Sunderland T

Cole BJ, Koob GF: Low doses of corticotropin-releasing factor potentiate amphetamine-induced stereotyped behavior 27

Commissaris RL → Schefke DM Cools AR → Spooren WPJM

Cooper SJ → Neill JC

Cooper T → Lieberman J Cornfeldt M → Locke KW

Corrigall WA, Coen KM: Fixed-interval schedules for drug self-administration in the rat 136

Corrigall WA, Coen KM: Nicotine maintains robust self-administration in rats on a limited-access schedule 473

Costello NL, Carlson JN, Glick SD, Bryda M: Dose-dependent and baseline-dependent conditioning with *d*-amphetamine in the place conditioning paradigm 244

Coward DM, Imperato A, Urwyler S, White TG: Biochemical and behavioural properties of clozapine S 6

Cowen PJ, McCance SL, Cohen PR, Julier DL: Lithium increases 5-HT-mediated neuroendocrine responses in tricyclic resistant depression 230

Cowen PJ → McCance SL Csernansky JG → Prosser ES Cumming G → Guyatt AR Cuypers E → Spooren WPJM

Danion J-M, Zimmermann M-A, Willard-Schroeder D, Grangé D, Singer L: Diazepam induces a dissociation between explicit and implicit memory 238

Daugé V, Rossignol P, Roques BP: Blockade of dopamine receptors reverses the behavioral effects of endogenous enkephalins in the *Nucleus caudatus* but not in the *Nucleus accumbens*: differential involvement of δ and μ opioid receptors 168

Deary IJ → Petrie RXA Delfs JM → Kelley AE

Devenport LD, Hale RL: Contributions of

hippocampus and neocortex to the expression of ethanol effects 337

Di Chiara G → Acquas E

Di Scala G, Sandner G: Conditioned place aversion produced by FG 7142 is attenuated by haloperidol 176

Eckernâs S-A → Lundberg T Edwards DJ → Caggiula AR Ekblom B → Lundberg T Elphick M: Effects of carbamazepine on dopamine function in rodents 532 Emmett-Oglesby MW: Reply to J.R. Hughes, S.T. Higgins, and W.K. Bickel:

Behavioral "properties" of drugs 422 Epstein LH → Caggiula AR Erfurth A → Schmauss M Etou H → Fujimoto K Ettenberg A → Weiss F

Farde L, Wiesel FA, Nordström A-L, Sedvall G: D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics S 28

Fasth KJ → Lundberg T Fehm HL → Born J

Fenwick JF → Hughes JR

Fernández-Guardiola A → Jurado JL

Fernández-Mas R → Jurado JL

Ferrari F, Tartoni PG, Monti A, Mangiafico V: Does anxiety underly imidazole-induced behavioural effects in the rat? 345

Field MJ → Rupniak NMJ Fielding S → Locke KW

File SE, Johnston AL: Lack of effects of 5HT<sub>3</sub> receptor antagonists in the social interaction and elevated plus-maze tests of anxiety in the rat 248

Fischer E → Gaertner HJ

Fleischhacker WW → Haring C Fleishaker JC, Phillips JP: Adinazolam pharmacokinetics and behavioral effects following administration of 20-60 mg oral doses of its mesylate salt in

healthy volunteers 34 Fontana DJ → Schefke DM Fredriksson A → Luthman J

Friedman E → Wang H-Y Fritze J, Laux G, Sofic E, Koronakis P, Schoerlin MP, Riederer P, Beckmann H: Plasma moclobemide and metabolites: lack of correlation with clinical response and biogenic amines 252

Fujimoto K, Sakata T, Ishimaru T, Etou H, Ookuma K, Kurokawa M, Machidori H: Attenuation of anorexia induced by heat or surgery during sustained administration of ginsenoside Rg<sub>1</sub> into rat third ventricle 257

Fukuda H → Shinotoh H

Gaertner HJ, Fischer E, Hoss J: Side effects of clozapine S 97 Gamble SJ → Annett LE García-Marquez C → Adell A Garver DL → Sanberg PR Gelders Y → Mesotten F Gelpí E → Adell A Gelpí E → Artigas F

George FR: Cocaine produces low dose locomotor depressant effects in mice 147

Gerlach J. Jørgensen EO. Peacock L: Long-term experience with clozapine in Denmark: research and clinical practice S 92

Gilbert ME, Mack CM: Enhanced susceptibility to kindling by chlordimeform may be mediated by a local anesthetic action 163

Giordano M → Sanberg PR

Glick SD → Costello NL

Gold LH, Hubner CB, Koob GF: A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA

Gold LH, Koob GF: MDMA produces stimulant-like conditioned locomotor activity 352

Goldberg SR → Takada K Golden RN → Risby ED

Gorney B → Locke KW

Grangé D → Danion J-M Grehn L → Herrera-Marschitz M

Griffiths RR → Roache JD

Grohmann R, Rüther E, Sassim N, Schmidt LG: Adverse effects of clozapine S 101

Grohmann R, Schmidt LG, Spieß-Kiefer C, Rüther E: Agranulocytosis and significant leucopenia with neuroleptic drugs: results from the AMÜP program S 109

Grohmann R → Naber D

Gudelsky GA, Nash JF, Berry SA, Meltzer HY: Basic biology of clozapine: electrophysiological and neuroendocrinological studies S 13

Gullberg P → Lundberg T Gulliver SB → Hughes JR Gunne LM → Liminga U

Guyatt AR, Kirkham AJT, Mariner DC, Baldry AG, Cumming G: Long-term effects of switching to cigarettes with lower tar and nicotine yields 80

Hagenmeyer-Houser SH → Sanberg PR

Hajek P → West R

Hale RL → Becker HC

Hale RL → Devenport LD

Halliday R, Callaway E, Lannon R: The effects of clonidine and yohimbine on human information processing 563

Hansen HJ → Loldrup D

Haring C, Meise U, Humpel C, Saria A, Fleischhacker WW, Hinterhuber H: Dose-related plasma levels of clozapine: influence of smoking behaviour,

sex and age S 38 Harland RD → Holloway FA

Haroutunian V → Santucci AC

Hartvig P → Lundberg T Haskett C → Mueller K

Heishman SJ, Stitzer ML: Effect of d-amphetamine, secobarbital, and marijuana on choice behavior: social versus nonsocial options 156

Helmchen H: Clinical experience with clozapine in Germany S 80

Herberg LJ, Rose IC: The effect of MK-

801 and other antagonists of NMDAtype glutamate receptors on brain-stimulation reward 87

Herning R → Muntaner C

Herrera-Marschitz M, Terenius L, Grehn L, Ungerstedt U: Rotational behaviour produced by intranigral injections of bovine and human B-casomorphins in rats 357

Heylen S → Mesotten F

Hienz RD, Brady JV: Diazepam and △-9-THC: contrasting effects on the discrimination of speech sounds in nonhuman primates 261

Hijzen TH, Slangen JL: Effects of midazolam, DMCM and lindane on potentiated startle in the rat 362

Hinterhuber H → Haring C

Hippius H: The history of clozapine S 3

Hippius H → Leppig M Hippius H → Naber D

Hirayama K → Shinotoh H

Holloway FA, King DA, Michaelis RC, Harland RD, Bird DC: Tolerance to ethanol's disruptive effects on operant behavior in rats 479

Honigfeld G, Patin J: Predictors of response to clozapine therapy S 64

Honigfeld G → Kane JM Hoss J → Gaertner HJ

Hsiao JK → Risby ED

Hubner CB → Gold LH

Hughes JR, Gulliver SB, Amori G, Mireault GC, Fenwick JF: Effect of instructions and nicotine on smoking cessation, withdrawal symptoms and self-administration of nicotine gum 486

Hull EM → Pehek EA Humpel C → Haring C

Hunter AJ, Murray TK: Cholinergic mechanisms in a simple test of olfactory learning in the rat 270

Huret JD → Baron JC

Imperato A → Coward DM Inoue O → Shinotoh H

Introduction S1

Introini-Collison IB, McGaugh JL: Cocaine enhances memory storage in mice 537

Ishimaru T → Fuiimoto K Itoh T → Shinotoh H

Iversen SD → Rupniak NMJ

lyo M → Shinotoh H

Jackson B → Trullas R

Jaffe AB, Sharpe LG, Jaffe JH: Rats selfadminister sufentanil in aerosol form 289

Jaffe J → Muntaner C Jaffe JH → Jaffe AB

Jennings CA → Rupniak NMJ

Johanson CE → Wit H de

Johansson P → Liminga U

Johns C → Lieberman J Johnston AL → File SE

Jonsson G → Luthman J

Jørgensen EO → Gerlach J Julier DL → Cowen PJ

Jurado JL, Fernández-Mas R, Fernández-Guardiola A: Effects of 1 week administration of two benzodiazepines on the sleep and early daytime performance of normal subjects 91

Kalant H → Le AD

Kalant H → San-Marina A Kamimori GH → Balkin TJ

Kane J → Lieberman J

Kane JM, Honigfeld G, Singer J, Meltzer HY, Clozaril Collaborative Study Group: Clozapine for the treatment-resistant schizophrenic: results of a US multicenter trial S 60

Kanof PD → Santucci AC

Kantak KM: Magnesium alters the potency of cocaine and haloperidol on mouse aggression 181

Katz JL → Takada K

Kelley AE, Bakshi VP, Delfs JM, Lang CG: Cholinergic stimulation of the ventrolateral striatum elicits mouth movements in rats: pharmacological and regional specificity 542

Kern W → Born J

Kesslick JM → Martin GE

Khanna JM → Le AD

Khanna JM → San-Marina A

King DA → Holloway FA

Kirkham AJT → Guyatt AR

Knopf S → Caggiula AR Knoth K → Sanders-Bush E

Ko GN → Potter WZ

Koob GF → Cole BJ

Koob GF → Gold LH

Koob GF → Weiss F

Koronakis P → Fritze J

Kostowski W → Plaznik A

Krupp P, Barnes P: Leponex - associated granulocytopenia: a review of the situation S118

Kumor KM → Muntaner C Kunko PM → Mueller K

Kurokawa M → Fujimoto K

Kwon KY → Meltzer HY

Laduron PM → Stutzmann J-M

Lang CG → Kelley AE Langemark M → Loldrup D

Lannon R → Halliday R

Laux G → Fritze J

Lawlor BA → Sunderland T

Le AD, Kalant H, Khanna JM: Roles of intoxicated practice in the development of ethanol tolerance 366

Leone P → Acquas E

Leppig M, Bosch B, Naber D, Hippius H: Clozapine in the treatment of 121 outpatients S 77

Leppig M → Naber D

Levin ED → McGurk SR

Lewander T → Luthman J

Lieberman J, Johns C, Cooper T, Pollack S, Kane J: Clozapine pharmacology and tardive dyskinesia S 54

Liminga U, Johansson P, Nylander I, Gunne LM: Intranigral infusion of enkephalins elicits dyskinetic biting in rats 299

Lindström LH: A retrospective study on the long-term efficacy of clozapine in

96 schizophrenic and schizoaffective patients during a 13-year period S 84

Lindström LH → Lundberg T Linnoila M → Bone GHA

Lloyd RL → Menon MK

Loc'h C → Baron JC

Locke KW, Gorney B, Cornfeldt M, Fielding S: Mu-opioid component of the ethylketocyclazocine (EKC) discriminative stimulus in the rat 492

Loldrup D, Langemark M, Hansen HJ, Olesen J, Bech P: Clomipramine and mianserin in chronic idiopathic pain syndrome. A placebo controlled study

Lundberg T, Lindström LH, Hartvig P, Eckernâs S-A, Ekblom B, Lundqvist H, Fasth KJ, Gullberg P, Långström B: Striatal and frontal cortex binding of 11-C-labelled clozapine visualized by positron emission tomography (PET) in drug-free schizophrenics and healthy volunteers 8

Lundqvist H → Lundberg T

Luthman J. Fredriksson A. Lewander T. Jonsson G, Archer T: Effects of d-amphetamine and methylphenidate on hyperactivity produced by neonatal 6hydroxydopamine treatment 550

Långström B → Lundberg T

MacAvoy MG → Marks DF

Machidori H → Fujimoto K

Mack CM → Gilbert ME

Majchrowicz E → Bone GHA

Mangiafico V → Ferrari F Marcusson JO, Andersson A, Bäckström 1: Drug inhibition indicates a single-site model of the 5-HT uptake site/antide-

pressant binding site in rat and human

brain 17 Mariner DC → Guyatt AR

Marks DF, MacAvoy MG: Divided attention performance in cannabis users and non-users following alcohol and cannabis separately and in combination 397

Martin GE, Mathiasen JR, Kesslick JM: Blockade of conditioned avoidance responding by trazodone, etoperidone, and MCPP 94

Martin PR → Bone GHA Martinez E → Artigas F

Martinot JL → Baron JC

Mathiasen JR → Martin GE

Maziere B → Baron JC

McCance SL, Cohen PR, Cowen PJ: Lithium increases 5-HT-mediated prolactin release 276

McCance SL → Cowen PJ

McGaugh JL → Introini-Collison IB

McGurk SR, Levin ED, Butcher LL: Radial-arm maze performance in rats is impaired by a combination of nicotiniccholinergic and D2 dopaminergic antagonist drugs 371

Meise U → Haring C

Meltzer HY, Bastani B, Kwon KY, Ramirez LF, Burnett S, Sharpe J: A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report S 68

Meltzer HY: Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia S18

Meltzer HY → Bastani B

Meltzer HY → Gudelsky GA

Meltzer HY → Kane JM

Meltzer LT, Serpa KA, Moos WH: Evaluation in rats of the somnogenic, pyrogenic, and central nervous system depressant effects of muramyl dipeptide 103

Menon MK, Lloyd RL: Involvement of noradrenergic system in a remarkably rapid tongue clonus produced by acute hypnotic doses of ethanol in Fischer F344 rats 497

Mesotten F. Suy E. Pietquin M. Burton P, Heylen S, Gelders Y: Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients 445

Michaelis RC → Holloway FA

Mireault GC → Hughes JR Mondadori C, Back M: Neural plasticity in vivo: opioid sensitivity of memory develops gradually after a septal lesion

Montgomery AMJ → Muscat R

Monti A → Ferrari F

Moos WH → Meltzer LT

Moser PC: An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone 48

Mucha RF, Ree JM van: Infusion ofγ<sub>2</sub>-MSH produce a conditioned taste aversion in morphine-dependent rats 140 Mueller EA → Sunderland T

Mueller K, Kunko PM, Whiteside D, Haskett C: Time course of amphetamineinduced locomotor stereotypy in an open field 501

Mueller K → Pettit HO

Muntaner C, Cascella NG, Kumor KM, Nagoshi C, Herning R, Jaffe J: Placebo responses to cocaine administration in humans: effects of prior administrations and verbal instructions 282

Murray TK → Hunter AJ

Muscat R, Montgomery AMJ, Willner P: Blockade of 8-OH-DPAT-induced feeding by dopamine antagonists 402 Muscat R, Willner P: Effects of dopamine

receptor antagonists on sucrose consumption and preference 98

Naber D → Leppig M

Naber D, Leppig M, Grohmann R, Hippius H: Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia - a retrospective study of 387 patients S 73

Nagoshi C → Muntaner C Nash JF → Gudelsky GA

Neill JC, Cooper SJ: Selective reduction by serotonergic agents of hypertonic saline consumption in rats: evidence for possible 5-HT<sub>1C</sub> receptor mediation

Newhouse PA → Sunderland T

Nil R, Bättig K: Separate effects of cigarette smoke yield and smoke taste on smoking behavior 54

Nordström A-L → Farde L Nutt DJ → Bone GHA Nylander I → Liminga U

O'Donnell VM → Balkin TJ Olesen J → Loldrup D Ookuma K → Fujimoto K Oswald I → Adam K

Patin J → Honigfeld G Peacock L → Gerlach J

Pehek EA, Thompson JT, Hull EM: The effects of intrathecal administration of the dopamine agonist apomorphine on penile reflexes and copulation in the male rat 304

Petrie RXA, Deary IJ: Smoking and human information processing 393

Pettit HO, Mueller K: Infusions of cholecystokinin octapeptide into the ventral tegmental area potentiate amphetamine conditioned place preferences 423

Phillips JP → Fleishaker JC Pierri J → Wit H de Pietquin M → Mesotten F Pietrowsky R → Born J

Plaznik A, Stefanski R, Kostowski W: Interaction between accumbens D<sub>1</sub> and D<sub>2</sub> receptors regulating rat locomotor activity 558

Poirier MF → Baron JC Pollack S → Lieberman J

Potter WZ, Ko GN, Zhang LD, Yan W: Clozapine in China: a review and preview of US/PRC collaboration S 87

Potter WZ → Risby ED

Prosser ES, Pruthi R, Csernansky JG: Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride 109

Pruthi R → Prosser ES

Ramirez LF → Meltzer HY Redmond DP → Balkin TJ Ree JM van → Mucha RF Referees in 1989 567 Ridley RM → Annett LE Riederer P → Fritze J

Risby ED, Hsiao JK, Golden RN, Potter WZ: Intravenous alprazolam challenge in normal subjects. Biochemical, cardiovascular, and behavioral effects 508

Roache JD, Griffiths RR: Diazepam and triazolam self-administration in sedative abusers: concordance of subject ratings, performance and drug self-administration 309

Rodgers RJ, Shepherd JK: Prevention of the analgesic consequences of social defeat in male mice by 5-HT<sub>1A</sub> anxiolytics, buspirone, gepirone and ipsapirone 374

Roques BP → Daugé V Rose IC → Herberg LJ Rossignol P → Daugé V

Rupniak NMJ, Steventon MJ, Field MJ, Jennings CA, Iversen SD: Comparison of the effects of four cholinomimetic agents on cognition in primates following disruption by scopolamine or by lists of objects 189

Russell KH → Sanberg PR Rüther E → Grohmann R Rüther E → Schmauss M

Sakata T → Fujimoto K

Sanberg PR, Russell KH, Hagenmeyer-Houser SH, Giordano M, Zubrycki EM, Garver DL: Neuroleptic-induced emotional defecation: effects of scopolamine and haloperidol 60

Sanders-Bush E, Breeding M, Knoth K, Tsutsumi M: Sertraline-induced desensitization of the serotonin 5HT-2 receptor transmembrane signaling system 64

Sandner G → Di Scala G

Sandyk R: Neuroleptic-induced akathisia: a role for MSH peptides 134

Sanger DJ: Discriminative stimulus effects of the  $\alpha_2$ -adrenoceptor antagonist idazoxan 117

San-Marina A, Khanna JM, Kalant H: Relationship between initial sensitivity, acute tolerance and chronic tolerance to ethanol in a heterogeneous population of Swiss mice 450

Santucci AC, Kanof PD, Haroutunian V: Effect of physostigmine on memory consolidation and retrieval processes in intact and nucleus basalis-lesioned rats 70

Saria A → Haring C Sarrias MJ → Artigas F Sassim N → Grohmann R

Schefke DM, Fontana DJ, Commissaris RL: Anti-conflict efficacy of buspirone following acute versus chronic treatment 427

Schmauss M, Wolff R, Erfurth A, Rüther E: Tolerability of long term clozapine

treatment S 105 Schmidt LG → Grohmann R Schoerlin MP → Fritze J Sedvall G → Farde L Serpa KA → Meltzer LT

Shanks N, Anisman H: Strain-specific effects of antidepressants on escape deficits induced by inescapable shock 122

Sharpe J → Meltzer HY Sharpe LG → Jaffe AB Shepherd JK → Rodgers RJ

Shinotoh H, Iyo M, Yamada T, Inoue O, Suzuki K, Itoh T, Fukuda H, Yamasaki T, Tateno Y, Hirayama K: Detection of benzodiazepine receptor occupancy in the human brain by positron emission tomography 202

Singer J → Kane JM Singer L → Danion J-M Sittig W → Born J Skolnick P → Trullas R Slangen JL → Hijzen TH Sofic E → Fritze J

Spieß-Kiefer C → Grohmann R Spooren WPJM, Cuypers E, Cools AR: Oro-facial dyskinesia and the sub-commissural part of the globus pallidus in the cat: role of acetylcholine and its interaction with GABA 381

Stassen HH → Angst J Stefanski R → Plaznik A

Steventon MJ → Rupniak NMJ

Stiller R → Caggiula AR Stitzer ML → Heishman SJ

Stutzmann J-M, Cintrat P, Laduron PM, Blanchard J-C: Riluzole antagonizes the anxiogenic properties of the β-carboline FG 7142 in rats 515

Ståhle L, Ungerstedt U: On the selectivity and specificity of the antagonism of apomorphine-induced suppression of exploration by sulpiride 75

Summary of discussions \$126

Sunderland T, Weingartner H, Cohen RM, Tariot PN, Newhouse PA, Thompson KE, Lawlor BA, Mueller EA: Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls 129

Suy E → Mesotten F Suzuki K → Shinotoh H Swedberg MDB → Takada K

Takada K. Swedberg MDB, Goldberg SR. Katz JL: Discriminative stimulus effects of intravenous /-nicotine and nicotine analogs or metabolites in squirrel monkevs 208

Tariot PN → Sunderland T Tartoni PG → Ferrari F Tateno Y → Shinotoh H Terenius L → Herrera-Marschitz M Thompson JT → Pehek EA Thompson KE → Sunderland T Toffano G → Zanotti A

Trullas R, Jackson B, Skolnick P: Genetic differences in a tail suspension test for evaluating antidepressant activity 287 Tsutsumi M → Sanders-Bush E

Udina C → Artigas F Ungerstedt U → Herrera-Marschitz M Ungerstedt U → Ståhle L Urwyler S → Coward DM

Valzelli L → Zanotti A Vittorio JA → Andorn AC

Wang H-Y, Friedman E: Lithium inhibition of protein kinase C activation-induced serotonin release 213

Weingartner H → Sunderland T

Weiss F, Ettenberg A, Koob GF: CCK-8 injected into the nucleus accumbens attenuates the supersensitive locomotor response to apomorphine in 6-OHDA and chronic-neuroleptic treated rats 409

Wenk GL: An hypothesis on the role of glucose in the mechanism of action of cognitive enhancers 431

West R, Hajek P, Belcher M: Time course of cigarette withdrawal symptoms while using nicotine gum 143

White TG → Coward DM

Whiteside D → Mueller K
Wiesel F-A → Alfredsson G
Wiesel FA → Farde L
Willard-Schroeder D → Danion J-M
Willetts J, Bobelis DJ, Balster RL: Drug
discrimination based on the competitive
N-methyl-D-aspartate antagonist, NPC
12626 458
Willner P → Muscat R

Wit H de, Pierri J, Johanson CE: Assessing pentobarbital preference in normal volunteers using a cumulative dosing procedure 416 Woggon B → Angst J Wolff R → Schmauss M

Yamada T → Shinotoh H Yamasaki T → Shinotoh H Yan W → Potter WZ

Zanotti A, Valzelli L, Toffano G: Chronic phosphatidylserine treatment improves spatial memory and passive avoidance in aged rats 316
Zhang LD → Potter WZ
Zimmermann M-A → Danion J-M
Zubrycki EM → Sanberg PR

## Subject Index of volume 99

Acetylcholine 70, 381, 542 Acoustic startle reflex 362 ACTH 4-10 439 ACTH analog 439 Acute 450 Acute extrapyramidal syndromes S47 Adinazolam 34 α2-Adrenergic 563 α<sub>1</sub>-Adrenergic system 497 α<sub>2</sub>-Adrenoceptors 117 Adverse drug reactions S80 Adverse effects S73 Aerosol 289 Affective disorders 287 Age S38 Aging 316 Agranulocytosis S77, S84, S109, S113 Alcohol 397 Alprazolam 508 Alzheimer's disease 129 Amfolenic acid 550 Amino acids 322 Amitriptyline 64, 122 Amphetamine 27, 222, 352, 423, 501, 532 AMÜP study S101, S109 Amygdala 163 Analgesia 233 Animal model 515 Animal models 287 Anorexia 257, 389 Antagonists 402 Anticholinergic 60 Antidepressants 287 Antidepressive agents 64 Antipsychotic drug treatment S28 Anxiety 48, 248, 345, 374, 427, 515 Anxiolytic efficacy 427 Apomorphine 75, 304, 409, 532 Attention 91, 439 Atypical neuroleptic 109 Autonomous side effects \$105 Aversion 176

Baboon 261 Basal ganglia 357 Baseline preference 244 Behavior 147 Behavioral effects 156 Behavioral pharmacology 156 Behavioral variability 337 Behaviour 381 Behavioural effects 181, S6 Benzodiazepine 129, 202 Benzodiazepines 91, 238, 309 Beta-carbolines 176 Bipolar patients 328 Blindness 486 Blood counts S122 Blood pressure 345, 508 Body temperature 103 Brain concentration 386 Brain slices 213 **Bupropion 122** Buspirone 48, 117, 374, 427

Calcium antagonists 386 Cannabis 397 Carbamazepine 532 **B-Carboline** 515 Carboxyhaemoglobin 80 Cardiovascular functions S92 β-Casein 357 Cat 381 Catecholamine 233 Catecholamines 508, 537, S32 Caudate nucleus 222 C57BL/6 mice 333 CGS 12066B 196 Chlordimeform 163 Cholecystokinin 409, 423 Cholinergic pathways 393 Cholinomimetics 189 Chronic 450 Chronic clomipramine 22 Chronic drug treatment 427 Chronic stress 22

Cigarette puffing 54 Cigarettes 80 Cigarette smoke taste 54 Cigarette smoke vield 54 Cigarette smoking 393 Cis-[Z]-flupenthixol 409 Clinical experience S 80 Clomipramine 1, 276 Clonidine 163 Clozapine 8, S6, S13, S18, S28, S38, S41, S47, S54, S64, S68, S73, S77, S80, S84, S92, S97, S105, S113 Clozapine + benzodiazepines S101 Clozapine adverse effects \$101 Clozapine monitoring form \$92 Clozapine plasma levels S32 Clozaril S 122 CNS depression 147 CO 54 Cocaine 13, 136, 147, 181, 282, 352, 537 Cocaine and reward 537 Cognition enhancers 431 Cognitive tests 129 Compensation 80 Conditioned avoidance blockade 94 Conditioned locomotion 352 Conditioned place preference 423 Conditioning 282, 389 Conflict behavior 427 Conflict procedures 515 Controlled stimulus processing 439 Corticosterone 233, S13 Corticotropin-releasing factor (CRF) 27 Cortisol S18 Cotinine 80 **CPP 458** d-Amphetamine 156, 244, 550, 563

Dantrolene 386 Daytime performance 91 D-1 Blockade S6 Defeat 374 Defecation 60 Delayed ethanol effect 479 Delayed nonmatching-to-sample 189 Depression 230 Desipramine 550 Desmethylimipramine 122 d-Fenfluramine 196 Diazepam 151, 261, 309, 386 Divided attention performance 397 **DMCM 362** d-Nicotine 208 Dopamine 13, 75, 98, 151, 304, 402, 409, 532, 550, S13, S18 Dopamine-D<sub>2</sub> antagonism 445 Dopamine receptor 109, 463 Dopamine receptors 8, 13 Dopamine receptor subtypes S 28 Dopaminergic mechanisms 558 Dose-response 244 Drug abuse 309 Drug discrimination 13, 117, 208, 458, Drug fever S 97 Drug-induced compensatory learning 479 Drug inhibition 17 Drug preference 416 Drugs S 113 Drug stimuli 13

Echocardiography S 92
EEG 103
Efficacy S73
Elevated plus-maze test 48
Endocrinological 445
Enkephalin analogues 299
Ethanol 333, 337, 386, 479, 497
Ethanol abuse 497
Ethanol interaction 103
Ethanol tolerance 366
Ethylketocyclazocine 492
Etoperidone 94
Event-related potential 202
Event-related potential (ERP) 439
Expectancy 486
Exploration 75

Dyskinetic biting 299

D<sub>1</sub> dopamine receptors 371

D<sub>2</sub> dopamine receptors 371

Fear-conditioning 362 Feeding 402 FG-7142 333 FG 7142 176, 515 Fischer rats 492 Fixed-interval 136 Fluoxetine 196 Fluperlapine S41 Frontal cortex 8

GABA 381
Genetic factors S113
Genetics 147
Gepirone 374
Ginsenoside Rg<sub>1</sub> 257
Globus pallidus 381
Glucose 431
Glutamate 87
Grooming 402

Haloperidol 60, 176, 181, 276, 409, 532, S41 Heated environment 257 Heroin 136 Hexamethonium 473 Hippocampus 337 Homogeneity 17 Homovanillic acid 252 Hormones S 32 <sup>3</sup>H-Spiroperidol 520 5-HT 196, 230, 276 5-HT<sub>2</sub> antagonism 445 5HT<sub>2</sub> antagonist 219 5-HT<sub>1A</sub> receptors 374 5-HT, receptor 196 5HT<sub>3</sub> receptors 248 Human 238 Human putamen 17 Humans 282, 309 Human speech 156 Human temporal cortex 520 6-Hydroxydopamine 40, 409, 550 5-Hydroxytryptamine<sub>1A</sub> receptors 48 Hyperactivity 550 Hypnotic 103 Hypothermia 366

Idazoxan 117
Imidazole 345
Immune mechanism S113
Implicit memory 238
Inbred mouse strains 287
Inescapable shock 122
Information processing 393, 563
Inspection time 393
Instructions 282
Intoxicated practice 366
Intranigral infusions 299
Ipsapirone 374

Kainate 87
Ketamine 87
Kindling 163
Knowledge memory 238
Kynurenic acid 87
/-Cotinine 208

Learning 389
Learning and memory 431
Leucopenia S97, S109
Lidocaine 163
Lindane 362
Lithium 213, 230, 276, 328
Liver enzymes S 97
/-Nornicotine 208
Locomotor activity 40, 147, 333, 558
Locomotor patterns 501
Locomotor stereotypy 501
Long-term trends 80

Magnesium 181
Major depression 1
Manic depression 532
Marijuana 156
Marmoset 222
mCPP 196
MDMA 40, 352
Mecamylamine 371, 473
Memory 70, 238, 537
Memory facilitation 294
Memory impairment 129, 309

Mesolimbic 109 Mesolimbic dopamine 40 Meta-chlorophenylpiperazine 94 Methylenedioxymethamphetamine 40 Methylphenidate 550 Mianserin 1 Mice 147, 374, 450 Microinjections 558 Midazolam 362 Mismatch negativity 439 MK-801 87 MK 212 196 Moclobemide 252 Monoamine metabolites 322 Monoamine oxidase 252 Monoamine oxidase inhibitors 252 Mono-N-desmethyladinazolam 34 Mood 439 Morphine 151, 294 Motor impairment 366 Mouth movements 542 Movement disorders S47 y2-MSH 140 Muramyl dipeptide 103

Naloxone 140, 151, 492 Narcosis 366 Nd 439 Negative symptoms S41, S77 Neonatal 550 Neuroendocrine challenge 508 Neuroleptic 60, S47 Neuroleptic drugs S109 Neuroleptics 463, S73, S84 Neurotransmitters S54 Nicotine 54, 151, 208, 389, 393, 473 Nicotine gum 143, 486 Nicotinic 371 Nimodipine 386 NMDA 87 N-methyl-p-aspartate 458 n-Methylscopolamine 60 Nociception 374 Non-opioid analgesia 374 Nootropics 431 Noradrenaline 22 Norepinephrine 252, 497 Normal volunteers 416 NPC 12626 458 Nucleus accumbens 40, 168, 222, 409, 558 Nucleus basalis of Meynert 70 Nucleus caudatus 168 8-OH-DPAT 402

Olfactory learning 270 Open field activity 287 Open field behavior 501 Operant performance 479 Opiate dependence 140 Opioid 289 Opioid receptors 357  $\mu$ ,  $\delta$  opioid receptors 168 Oral behavior 542 Oro-facial dyskinesia 381

P3 439
Pain 1
Parkinsonism S105
[3H]paroxetine binding 17
Passive avoidance 294, 316

Patient Management System S122 Penile reflex 304 Pentobarbital 416 Peptidase inhibitor 168 Pharmacokinetics 34, 445, S32 Pharmacology S54 Phencyclidine 87, 151, 458 Phorbol esters 213 Phosphatidylserine 316 Phosphoinositides 64 Physostigmine 70, 542 Picrotoxin 151 (-)Pindolol 374 Place-aversion 151 Placebo 282 Place conditioning 176, 244 Place-preference 151 Plasma 5-hydroxyindoleacetic acid 328 Plasma levels S38 Plasma serotonin 328 Platelet serotonin uptake 328 Plus-maze 248 Positron emission tomography 8, 202, 463 Positron Emission Tomography S28 Postpartum psychosis 357 Prefrontal cortex 337 Prolactin S 13, 276, 463 Protein kinase C translocation 213 Psychomotor effects 34 Psychomotor performance 526 Psychopathology S32 Puffing behaviour 80

## Quality of life S68

Raclopride 371
Radial-arm maze 371
Radial maze 337
Rat 13, 27, 87, 98, 140, 248, 270, 299, 304, 316, 352, 362, 366, 402, 473, 515, 558
Rat brain 357
Rat cortex 17
Rating scales S41
Rats 70, 117, 337, 458, 550
Rat third ventricle 257
Reaction time 91, 393, 563
Receptor 202
Receptors 13
Reinforcement 244, 423, 473, 486

Respiratory inhalation 54
Reward 423
Rhesus monkey 189
Riluzole 515
Risperidone 445
Ritanserin 219
Ro15-1788 202
RO15-4513 333
Rotational behaviour 357
RU 24969 196
3S
60S

**87S** Salt intake 196 SCH-23390 98 SCH 23390 75, 151, 371 Schizophrenia 8, 322, S54, S64, S73, S77, S84, S92 Scopolamine 60, 189, 270, 563 Secobarbital 156 Second messenger 8 Second-order schedule 136 Sedation 34 Seizures 163 Selective drugs 558 Self-administration 136, 289, 309, 473 Self-stimulation 87 Sensitivity 450 Sensitization 233 Septal lesion 294 Septal lesions 270 Serotonin 22, 64, 374, S18 Serotonin and norepinephrine release 213 Serotonin receptors 64, 520 Sertraline 64 Serum 322 Sex S 38 Sexual behavior 304 Shuttle escape 122

Side effects S32, S77, S97 SKF 38393 75 Sleep 91, 219 Sleep-awake cycle 103 Sleep deprivation 526 Sleep stage 526 Slow wave sleep 219 Smoking 143, S38 Smoking cessation 486 Social behavior 156 Social behaviour 222 Social interaction 248 Spatial delayed response 189 Spatial memory 316 Speech sound discriminations 261 Spinal cord 304 State-dependency 537 Stereotypy 27, 501 Strains 122 Stress 233 Striatum 109, 463, 542 Subjective effects 156 Subjective responses 416 Sucrose preference 98 Sufentanil 289 Sulpiride 75, 98, 322 Supersensitivity 109, 409 Surgery 257

Tardive dyskinesia 299, S47, S54, S73, S77, S105 Taste aversion 140 Taste preference conditioning 140 TFMPP 196 △-9-THC 261 Therapeutical efficacy S 80 Therapeutic response S 64 Thioproperazine 168 Thirst 196 Time-course 143 Tobacco withdrawal 486 Tolerance 389, 450, 479 Tongue dyskinesias 497 Trazodone 94 Treatment-resistant schizophrenia S 68 Tremor 386 Triazolam 309, 526 Tricyclic antidepressant 230 Tryptophan 230, S 18 Two-bottle test 98

Vapor 289 Vehicle effects 386 Ventral tegmental area 423

Withdrawal 219, 386 Withdrawal motivation 140 Withdrawal symptoms 143

Yohimbine 117, 345